Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here...

Full description

Bibliographic Details
Main Authors: Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Hui Zhang, Ju Bai, Yan Xu, Han Zhu, Juan Du, Hua Jiang, Xiao-Hu Fan, Jian-Yong Li, Jian Hou, Zhu Chen, Wang-Gang Zhang, Jian-Qing Mi, Sai-Juan Chen, Ai-Li He
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Journal of Hematology & Oncology
Subjects:
Multiple myeloma
Chimeric antigen receptor therapy
B cell maturation antigen
Safety
Efficacy
Online Access:https://doi.org/10.1186/s13045-022-01301-8

Internet

https://doi.org/10.1186/s13045-022-01301-8

Similar Items